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Abstract
Background: Human African trypanosomiasis (HAT) or sleeping sickness leads to a complex neuropsychiatric syndrome with
characteristic sleep alterations. Current division into a first, hemolymphatic stage and second, meningoencephalitic stage is
primarily based on the detection of white blood cells and/or trypanosomes in the cerebrospinal fluid. The validity of this
criterion is, however, debated, and novel laboratory biomarkers are under study. Objective clinical HAT evaluation and
monitoring is therefore needed. Polysomnography has effectively documented sleep-wake disturbances during HAT, but
could be difficult to apply as routine technology in field work. The non-invasive, cost-effective technique of actigraphy has
been widely validated as a tool for the ambulatory evaluation of sleep disturbances. In this pilot study, actigraphy was
applied to the clinical assessment of HAT patients.
Methods/Principal Findings: Actigraphy was recorded in patients infected by Trypanosoma brucei gambiense, and age- and
sex-matched control subjects. Simultaneous nocturnal polysomnography was also performed in the patients. Nine patients,
including one child, were analyzed at admission and two of them also during specific treatment. Parameters, analyzed with
user-friendly software, included sleep time evaluated from rest-activity signals, rest-activity rhythm waveform and
characteristics. The findings showed sleep-wake alterations of various degrees of severity, which in some patients did not
parallel white blood cell counts in the cerebrospinal fluid. Actigraphic recording also showed improvement of the analyzed
parameters after treatment initiation. Nocturnal polysomnography showed alterations of sleep time closely corresponding
to those derived from actigraphy.
Conclusions/Significance: The data indicate that actigraphy can be an interesting tool for HAT evaluation, providing
valuable clinical information through simple technology, well suited also for long-term follow-up. Actigraphy could
therefore objectively contribute to the clinical assessment of HAT patients. This method could be incorporated into a clinical
scoring system adapted to HAT to be used in the evaluation of novel treatments and laboratory biomarkers.
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Introduction
Human African trypanosomiasis (HAT), commonly known as
sleeping sickness, is caused by subspecies of the protozoan parasite
Trypanosoma brucei (T.b.) and transmitted by tsetse fly bites in sub-
Saharan Africa. This disease, which mainly affects rural
populations, is one of the most neglected tropical diseases, and is
fatal if left untreated [1–3]. There are two forms of the disease: the
West and Central African form caused by T.b. gambiense, which
represents the vast majority of cases, and the East African form
caused by T.b. rhodesiense. The disease evolves in two stages:
hemolymphatic (stage 1) and meningoencephalitic (stage 2), which
require different treatments. The arsenical compound melarsoprol
has been widely used for stage 2 disease, but this therapeutic
approach has severe side-effects, including fatal complications [3].
The main criterion for disease staging relies principally on the
detection of elevated white blood cell (WBC) number and/or
trypanosomes in the cerebrospinal fluid (CSF) [4]. The validity of
this criterion is, however, under debate [5–8], information on
its correlation with clinical disease severity is limited, and new
laboratory biomarkers for disease staging are currently under
evaluation [7,9–13]. Objective clinical methods, preferably non-
invasive, are therefore needed not only for the examination of
HAT patients but also for follow-up, correlation with stage
biomarkers, evaluation of treatment results and assessment of
clinical trials.
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1525HAT leads to a constellation of neurological and psychiatric
alterations, with characteristic sleep disturbances [2,14–18]. In
fact, in a prospective multinational study of a large cohort of HAT
patients, sleeping disorder, subjectively reported by the patients
mostly as insomnia, was found to be the leading clinical symptom
of the disease [17]. Sleep alterations have been repeatedly
proposed as main signs of central nervous system involvement in
HAT [3,15,19], although their relationship with HAT staging is
not yet fully established.
The technique of polysomnography (PSG) has documented in
detail sleep disturbances in HAT [14–16], showing that the disease
is characterized by disruption of the sleep-wake cycle during 24 h,
with nocturnal insomnia and daytime sleepiness, and thus drawing
attention also to disturbances of daily biological rhythms. The
structure of sleep, and especially the sequence of the two types of
sleep, namely rapid eye movement (REM) sleep which should be
normally preceded by non-REM (NREM) sleep, is also frequently
altered in HAT, with the occurrence of sleep-onset REM
(SOREM) episodes [15] in which REM sleep is preceded by
wakefulness. These disturbances are improved or reversed by
treatment, indicating that they are disease-related signs [15,20].
PSG has been proposed as a non-invasive technique also for the
evaluation of children affected by HAT [19]. However, PSG
recordings are cumbersome, relatively expensive and difficult to
perform in resource-limited health centers, and may not,
therefore, represent a routine procedure for HAT in the field.
This has led us to the search for less expensive and more user-
friendly non-invasive technologies to allow objective assessment of
day/night disturbances during the disease. A method developed in
the last years is actigraphy, based on movement recordings via
battery-run activity sensors, the actigraphs, wrist-watch size
devices mostly worn on the wrist. Collected data are then
downloaded to a portable computer and analyzed to provide an
estimate of alterations of rest-activity from which sleep-wake
parameters are analyzed [21,22].
Actigraphy has been developed and validated for human
circadian rhythm disorders and sleep disturbances. Although
actigraphy does not reach the level of information on sleep and
wake parameters obtained by PSG, this technique provides a non-
invasive, reliable tool for the ambulatory assessment of sleep
disorders and the effects of treatment designed to improve sleep
[21,23–25]. Actigraphy is used in a variety of clinical conditions
(see, for example, [26–28]), and has been increasingly used also in
children [21,29].
According to WHO guidelines, second stage HAT is defined by
the detection in the CSF of .5 WBC/ml [4], but different cut-off
criteria are used in some African countries where HAT is
prevalent. In particular, a parameter of .5u pt o#20 WBC/ml
CSF, defining an intermediate stage of disease, is also used before
second stage drug treatment is initiated [8,17,30,31]. Since
objective tests of HAT symptoms are urgently needed for clinical
assessment of the patients and treatment follow-up under field
conditions, we here undertook a pilot study based on actigraphic
recordings of patients infected by T.b. gambiense in different stages
of disease.
The investigation was conducted in two phases. First, actigraphy
was performed in Cameroonian patients before and after the
initiation of treatment. These findings have been previously
reported in part in abstract form [32]. The study was then pursued,
in the Democratic Republic of Congo (DRC), with actigraphic
recordings of HAT patients at admission. Nocturnal PSG was
recorded simultaneously to actigraphy. All the parameters derived
from actigraphy have been analyzed with a user-friendly software
which can be easily applied under field conditions. Altogether the
findings point to actigraphy as a useful, non-invasive tool for an
objective clinical assessment and monitoring of HAT.
Materials and Methods
Study sites and patient recruitment and clinical
evaluation
Two patients (Y1 and Y2) were investigated and treated in the
Neurology Department of the Central Hospital of Yaounde ´,
Cameroon (Table 1). This is one of the countries known to be
endemic for HAT, classified among those with less than 100 new
cases per year [6] with 5 foci of the disease [33,34]. The patients
were referred by the National Trypanosomiasis Control Pro-
gramme of the Ministry of Public Health during a screening
campaign for HAT after positive screening for antibodies against
T.b. gambiense in the blood with the card agglutination test for
trypanosomiasis (CATT). Both patients presented with histories of
various complaints, including nocturnal insomnia and diurnal
somnolence. CSF analysis was done according to standard
methods at the Centre Pasteur Laboratory in Yaounde ´. On the
basis of the CSF finding of 6 WBC/ml, the patients were diagnosed
as intermediate stage HAT (see above), and were treated with a
10-day course of pentamidine (4 mg/kg daily, administered
through the deep intramuscular route). The drug was supplied
free of charge through the World Health Organization system.
Actigraphic recordings were performed at admission after the
initiation of treatment. The patients kept a diary of daily activities
throughout the investigation. Nocturnal PSG was recorded in
patient Y2 simultaneously with actigraphy before and after
treatment. Actigraphy of healthy, age- and sex-matched control
subjects (CY1 and CY2) was recorded in parallel with the first
actigraphic recordings of patients Y1 and Y2.
Seven patients (K1–K7; Table 1) were investigated in DRC,
which is classified to be among the countries with more than 1000
HAT cases per year [6,34] and with considerable underreporting
[35]. All the patients had just come to observation through the
National Sleeping Sickness Control Programme (NSSCP) of the
Ministry of Health and had not yet received specific treatment.
Author Summary
The clinical picture of the parasitic disease human African
trypanosomiasis (HAT, also called sleeping sickness) is
dominated by sleep alterations. We here used actigraphy
to evaluate patients affected by the Gambiense form of
HAT. Actigraphy is based on the use of battery-run, wrist-
worn devices similar to watches, widely used in middle-
high income countries for ambulatory monitoring of sleep
disturbances. This pilot study was motivated by the fact
that the use of polysomnography, which is the gold
standard technology for the evaluation of sleep disorders
and has greatly contributed to the objective identification
of signs of disease in HAT, faces tangible challenges in
resource-limited countries where the disease is endemic.
We here show that actigraphy provides objective data on
the severity of sleep-wake disturbances that characterize
HAT. This technique, which does not disturb the patient’s
routine activities and can be applied at home, could
therefore represent an interesting, non-invasive tool for
objective HAT clinical assessment and long-term monitor-
ing under field conditions. The use of this method could
provide an adjunct marker of HAT severity and for
treatment follow-up, or be evaluated in combination with
other disease biomarkers in body fluids that are currently
under investigation in many laboratories.
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CATT screening and disease stages were defined on the basis of
CSF analysis as above (Table 1). Nocturnal PSG recordings were
performed simultaneously with actigraphy, upon arrival, in the
‘‘Institut National de la Recherche Biome ´dicale’’ (INRB) in
Kinshasa. The patients were then transferred to a hospital in
Kinshasa (‘‘Centre Hospitalier Roi Baudouin I’’ or ‘‘Centre
Neuro-Psycho-Pathologique’’, CNPP), in collaboration and con-
formity with the procedures of the NSSCP for initiation of
treatment. Actigraphic recordings were also done, in the same
environments, on age- and sex-matched control subjects (CK1–
CK7), who were CATT-negative.
The patients had a thorough general and neurological
examination. HIV serology was negative in all the patients and
control subjects.
Actigraphic and polysomnographic recordings
For actigraphy, octagonal BASIC MotionloggerH actigraphs
(Ambulatory Monitoring, Inc., New York, NY, USA) were worn
by the subjects on the non-dominant wrist. Throughout the
recording period, the actigraphs were only removed when the
subject was taking a shower to avoid damage by water to the
device.
For PSG, electrodes were placed to record the electroenceph-
alogram (EEG), electrooculogram, and electromyogram according
to standard procedures (see also [15]). The standard 10/20 system
was used to place EEG electrodes on the scalp of the subjects. A
computerized system equipped with Neuron Spectrum PSG
software (NeuronsoftH, Geneva, Switzerland) was used to filter,
record, and store the tracings obtained.
In patient Y1, 24 h actigraphic recordings were done upon
admission and at day 55 after the initiation of treatment. In patient
Y2, 36 h actigraphic recordings were performed before treatment
and 14 days after the initiation of treatment, and 12 h PSG
recordings were performed simultaneously with actigraphic
recording during the night. In patients K1–K7, 36 h actigraphic
recordings were performed at presentation, together with 12 h
PSG recordings during the night.
No difficulties were encountered during actigraphic recordings,
whereas for PSG several challenges were faced at the Neurology
Department of the Yaounde ´ Central Hospital as well as at INRB
in Kinshasa, especially due to electrical power failures (which also
caused non-recording or loss of PSG data for patients Y1 and K7).
Ethics statement
The study was conducted according to the principles expressed
in the Declaration of Helsinki. All patients recruited received
written and verbal information explaining the purpose of the study
and gave informed consent. Ethical consent forms were designed
in English and French in Cameroon and in French in DRC, and
were also translated into local languages during administration.
For the participation of the 5 year-old patient and matched control
child, consent was given by the parents. The protocols received
approval and ethical clearance by the Cameroon National Ethics
Committee, and authorization by the Ministry of Public Health of
Cameroon, as well as by the National Ethics Committee of the
Democratic Republic of Congo and the Ministry of Health
National Sleeping Sickness Control Program. All patients were
hospitalized and cared free of charge in the Neurology Depart-
ment of the Central Hospital Yaounde ´ for the Cameroonian
patients and in the ‘‘Centre Hospitalier Roi Baudouin I’’ or CNPP
for the Congolese patients. All hospitalization charges were paid
by the research project funds.
Data analysis and statistical evaluation
The raw data of activity over time (actigram) were displayed on
a portable computer (Figs. 1 and S1). Analysis of the actigrams was
performed with the Action 4 version 1, a user-friendly software
supplied by the manufacturer of the actigraphs (Fig. S1). Following
the software steps (Fig. S1), the algorithm of Sadeh [22,36] was
applied to the rest-activity (RA) signals to estimate the total sleep
time during the night (the daily suggestive period of rest: from 10
PM to 7 AM), and the day (the daily suggestive period of activity:
from 10 AM to 7 PM).
In addition, using the same software (and the steps illustrated in
Fig. S1), raw activity values were analyzed to obtain information
on the 24 h RA rhythm using the cosinor rhythmometry method
(see supporting information S2). The Action 4 software, as well as
software provided by other actigraph manufacturers allow to
perform such analyses in a few rapid steps which can be easily
learned without extensive training. Cosinor rhythmometry anal-
yses provide an F-ratio, which reflects the degree of fragmentation
of the RA signal: the more the tracing is fragmented, the lower is
the associated F-ratio. Data were also obtained on the character-
istics of the RA rhythm and, in particular, the rhythm-adjusted
mean (MESOR), amplitude, and peak activity time or acrophase
[37,38] (see supporting information S2).
Table 1. Data on subjects investigated in the present study.
Y1 Y2 K1 K2 K3 K4 K5 K6 K7
Age (years) 3 92 75 3 05 05 16 24 52 5
Sex M FFFFFM FM
Country of origin CMR CMR DRC DRC DRC DRC DRC DRC DRC
CSF WBC count* 6635662 7 9 3 5 1 1 5 0
Disease stage int. int. 1 1 int. int. 2 2 2
CY1 CY2 CK1 CK2 CK3 CK4 CK5 CK6 CK7
Age (years) 4 22 75 3 04 35 06 24 72 7
Sex M FFFFFM FM
Country of origin CMR CMR DRC DRC DRC DRC DRC DRC DRC
*Trypanosoma brucei were not detected in any of the CSF samples.
Abbreviations: CMR: Cameroon; CSF: cerebrospinal fluid; DRC: Democratic Republic of Congo; int: intermediate; WBC: white blood cell.
doi:10.1371/journal.pntd.0001525.t001
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Spectrum PSG software mentioned above, and the total sleep time
during the night (from 10 PM to 7 AM) was determined.
Statistical evaluation was conducted on data derived from the
recordings performed in DRC, for which groups of subjects were
available. The sleep total time during day or night, respectively,
was evaluated with the Student’s unpaired t test in the adult
patients K2–K7 versus the matched control group of adult subjects
(CK2–CK7). P values lower than 0.05 were considered significant.
Results
HAT patients in Cameroon
On observation of 24 h actigrams of patient Y1 before
treatment, bouts of high activity were evident during the night,
indicating disturbed sleep. The actigram of patient Y2 showed
more marked alterations, which consisted not only of bouts of high
activity during the night but also of a fragmented activity during
the day, frequently interrupted by episodes of rest indicative of
episodes of diurnal somnolence (Fig. 1B), as compared to the
control (Fig. 1A).
Quantitative analyses of the actigrams recorded in these patients
before treatment showed that in patient Y1 the total time spent
asleep corresponded to 20% of the day (versus 2% in the matched
control subject) and 59% of the night (versus 81% in the control)
(Fig. 2A,B). In patient Y2 the time spent asleep corresponded to
44% of the day and 60% of the night (versus 1.8% and 96.3%,
respectively, in the matched control subject) (Fig. 2C,D).
The alterations revealed by the actigraphic recordings showed
an improvement after the initiation of treatment. In patient Y1 the
number and amplitude of bouts of activity during the night
decreased with respect to the pre-treatment recording. Analysis of
the actigram at 55 days after treatment showed that the total time
spent asleep had decreased to 12% of the day and increased to
73% of the night (Fig. 2A,B). In patient Y2, the actigram pattern
seemed to have improved especially during daytime at 14 days
after treatment (Fig. 1C), as confirmed by the analyses which
showed a marked decrease of the time spent asleep during the day
(23%) and a slight increase of the sleep time at night (64%)
(Fig. 2C,D).
Nocturnal PSG recordings were also made in patient Y2, so
that the actigram and concomitant hypnogram could be com-
pared (Fig. 3). The analysis of sleep time from PSG indicated
that before treatment patient Y2 spent asleep 47% of the night,
which increased to 58% at two weeks after treatment (Fig. 2D).
Such values indicated that in this patient actigraphy had
overestimated the proportion of sleep during the night as
compared to PSG, which, as it will be discussed further, is a
possible limitation of this technique [22]. Nevertheless, both RA
and PSG recordings showed a reduction of the patient’s sleep time
during the night with an improvement after treatment, though
actigraphy underestimated the post-treatment improvement of this
parameter.
Figure 1. Actigrams of a patient and of a control subject.
Actigrams are 36-h long, and correspond to tracings from the control
subject CY2 (A) and patient Y2 before treatment (B) and at 14 days after
initiation of treatment (C). The horizontal bars indicate the light and
dark periods.
doi:10.1371/journal.pntd.0001525.g001
Figure 2. Total sleep time estimated from actigraphic record-
ings. The total sleep time was estimated from actigraphic recordings
(RA, rest-activity) in control subjects CY1 and CY2, and in patients Y1
and Y2 before and after treatment (T) initiation and, in patient Y2, also
with simultaneous nocturnal polysomnography (PSG). ‘‘Day’’ corre-
sponds to the suggestive daily time of maximal activity and ‘‘night’’ to
the suggestive daily interval of rest. A,B illustrate data obtained in
patient Y1 and matched control subject; C,D illustrate data obtained in
patient Y2 and matched control subject.
doi:10.1371/journal.pntd.0001525.g002
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correspondence in patient Y2, in particular revealing activity bursts
and wakefulness episodes (Fig. 3). However, SOREM episodes
observed in the hypnogram before and after treatment (Fig. 3) were
not shown by the actigrams. This is due to the fact that, as also
discussed further, algorithms used to estimate sleep from RA
consider short intervalsofactivity and arethereforenot suited for the
detection of brief, single epoch events [22], such as SOREM events.
Analysis of the RA signal and rhythm characteristics (Fig. 4A,B)
provided further objective demonstration of disease-related signs
in these patients. The waveform of the activity data (fitting curve)
allowed the visualization of the daily curve of the rhythm (Fig. 4A).
This clearly showed an alteration in patients Y1 and Y2 at
admission, which was less marked, especially in patient Y1, after
treatment (Fig. 4C,D). The value of the F-ratio, which was
decreased in both patients and especially in patient Y2, also
showed a post-treatment increase, indicating clinical improvement
(Fig. 4C,D). In particular, before treatment the F-ratio value was
228 in patient Y1 (446 in control subject CY1), and 87 in patient
Y2 (970 in control subject CY2). During treatment this value
increased to 293 in patient Y1 and 286 in patient Y2. Evaluation
of the rhythm characteristics (acrophase, MESOR and amplitude)
showed different degrees of alteration in the patients and partial
recovery after treatment (Fig. 4C,D).
HAT patients in DRC
As mentioned previously, 36 h actigraphy and simultaneous
12 h nocturnal PSG were performed in patients K1–K7, including
one child (K1), who were analyzed at admission (Table 1).
The actigrams of the adult patients compared to the matched
controls showed varying degrees of alterations (Fig. 5). In the 2
patients with very high WBC number in the CSF (K6 and K7), the
actigrams revealed a complete disruption of the day/night cycle
(Fig. 5H,I). The analysis of sleep time showed that these patients
had sleep episodes accounting for a considerable proportion of the
day (K6: 31.8%, K7: 33.7% of sleep time versus less than 1% in the
respective controls), and a considerable decrease of the time spent
asleep during the night (K6: 57.2%, K7: 39.9%, versus about 80%
in the respective controls) (Fig. 6A,C).
The alterations were less marked in most of the other adult
patients (Figs. 5D–G, 6). However, when considering the severity
of alterations revealed by actigraphy and the WBC counts in the
CSF, discrepancies were noted. The actigrams appeared altered in
2 patients with WBC counts corresponding to 5 and 6 cells,
respectively (Fig. 5D,F), while they were relatively preserved not
only in another patient with a WBC count of 6 cells (Fig. 5E), but
also in a patient with WBC count of 27 cells (Fig. 5G).
Quantitative analyses of the proportion of sleep time in the adult
patients K2–K4 revealed corresponding alterations especially
during the night (Fig. 6C), with a considerable increase of time
spent asleep during the day in patient K4 (23.5% versus 0.6% in the
control) (Fig. 6A). Analyses derived from simultaneous nocturnal
PSG recordings in the adult patients K2–K6 showed a good
correspondence with the RA signal in actigraphy, though the latter
overestimated sleep time in one patient (K2) (Fig. 6C), as noted
above for patient Y2.
The statistical analysis showed a significant difference in the
average time spent asleep during day and night, respectively, in the
group of adult HAT patients versus the control group, with
significant increase of the total sleep time during the day and
decrease during the night (P,0.05 for both parameters) (Fig. 6B,D).
In the 5-year old child infected by T.b. gambiense with a WBC
count in the CSF of 3 cells, actigraphy revealed marked functional
alterations compared with the healthy child of the same age and sex
(Fig. 7).The actigramof this patientappeareddisrupted(Fig. 7A), as
reflected by the quantitative evaluation of the sleep time, which
corresponded to 37.8% of the day (versus 0.76% in the control child)
(Fig. 7B) and 62.7% of the night (versus 90% in the control) (Fig. 7C).
The nocturnal PSG recordingprovided the same value of sleep time
(62.4%) (Fig. 7C) as that derived from actigraphy.
SOREM episodes were observed in all DRC patients except in
K6 (Fig. S2) (in K7, as mentioned previously, PSG data were
corrupted and therefore not scored).
The analysis of the rhythm waveform showed in the patients
different degrees of alterations of the daily pattern and rhythm
parameters (Fig. 8A–G). The statistical evaluation of the rhythm
characteristics in the adult patients confirmed a significant mean
decrease of the F-ratio with respect to the matched control group
(P,0.01) (Fig. 8H). These analyses also showed a significant
decrease of the mean values of the MESOR and amplitude
(P,0.05 for both parameters), with a preserved mean value of
acrophase time, thus indicating that the time of peak activity was
less affected than the other rhythm characteristics (Fig. 8H).
Discussion
Ourpilotstudyshowsthat actigraphyduringHATcaneffectively
reveal sleep-wake alterations characteristic of this disease and
Figure 3. Comparison of nocturnal actigrams and hypnograms. The nocturnal actigrams (12-h long) (upper) and corresponding hypnograms
(lower) of patient Y2 before (A) and after (B) treatment initiation are shown. Note in A the long bouts of activity corresponding to wakefulness (W)
which therefore cause sleep disruption; note in B the improvement of these signs of disease (decrease of night activity with improvement of the
hypnogram pattern) at 14 days after treatment initiation. Note also the close correspondence between actigrams and hypnograms, with the
exception of sleep-onset REM sleep (SOREM) episodes (arrows) detected in the hypnogram only. The horizontal bars indicate the light and dark
periods. Other abbreviations: R: rapid eye movement (REM) sleep, N1–N3: phases of non-REM sleep.
doi:10.1371/journal.pntd.0001525.g003
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eters, such as the night sleep disruption and the infiltration of
episodes of sleep during the day, pointed out by previous PSG
studies [15], were well reflected by the actigrams. Furthermore,
simultaneous actigraphic and PSG recordings during the night have
shown in the present study a good correspondence of the two
techniques in revealing sleep disturbances.
The use of PSG has contributed to significant progress in the
diagnosis of neurophysiological alterations duringHAT [14–16,20],
and this technology remains the gold standard for the analyses of
sleep-wakedisorders.However,PSGmayhaveseriouslimitationsin
HAT endemic settings. Compared to PSG, actigraphy requires
much simpler and cost-effective equipment (a dry-cell battery-run, a
watch-size device and a laptop). The software (5.5 megabytes) can
run on a portable computer, and the files of the actigrams (21
kilobytes) can be easily transferred through a cellular phone, or
attached to e-mail messages even with slow internet connections,
making very easy the acquisition and transfer of data for analyses.
Thebattery-run actigraphcanrecordand storedata forseveraldays
without the risk of data loss due to electrical power failures (which
canfrequently occur in field studies and did occur duringourstudy).
The possibility of an easy use of actigraphy in the field needs
requires confirmation in future studies, but it should also be
considered that can be done at home, and is thus well suited for
long-term studies without interfering with the subject’s routine
activities [22].
In our investigation, the qualitative observation of actigraphic
recordings showed in the cohort of 8 adult patients (Y1 and Y2,
and K2–K7) varying degree of alterations. These ranged from well
evident, high bouts of activity during the night, and therefore with
considerable sleep fragmentation, to the complete disruption of the
sleep-wake cycle. In patients Y1 and Y2, actigraphy showed an
improvement of the signal parameters after treatment initiation.
These findings tally with previous studies based on PSG recordings
[20], which have in addition shown that complete recovery of
sleep-wake parameters in HAT patients requires a very long time,
and symptoms may persist for months after the end of treatment.
A longitudinal long-term assessment is therefore required,
actigraphy is especially suited for this purpose.
The present observation in the child affected by HAT (K1) is in
accordance with previous evidence that actigraphy is valid for an
evaluation of sleep-wake in children [29,36]. This finding is also in
accordance with a recent report that sleep alterations reflect HAT
severity in children [19]. The present preliminary evidence of the
efficacy of actigraphy in a child affected by HAT is of particular
interest especially considering the great difficulty in the evaluation
of clinical signs (such as inactivity and unusual behavior) in
children of 1–6 years of age suffering from this disease [17].
Although actigraphy is not a routine procedure in the
evaluation of brain and/or systemic infections, data have been
obtained with actigraphic recording in persons living with HIV
infection [39,40], given that sleep disturbance is a common
complaint during this infection. These studies have been
performed in HIV-infected women with CD4 cell counts between
40 and 930 mm
3, and using as exclusion criteria AIDS-dementia
diagnosis, neuropathy or use of illicit drugs. The investigations
have shown a moderate reduction of sleep time during the night
with napping episodes during the day, providing an objective
evaluation of the patients’ complaints of insomnia and fatigue
[39,40]. These alterations do not configurate, however, the
fragmentation of the sleep pattern and sleep-wake cycle charac-
teristic of HAT.
Limitations of actigraphy were also evident in our pilot study.
SOREM episodes, detected in the hypnograms of our HAT
patients in agreement with previous findings [15], could not be
differentiated from normal rest in the actigraphic recording.
Furthermore, the simultaneous actigraphic and nocturnal PSG
recordings showed that in some of the adult cases the analysis
derived from actigraphy tended to overestimate the total sleep
time. As mentioned above, this limitation is inherent to the
technique, due to the difficulty to distinguish sleep from episodes in
which the subject wakes up but remains motionless [22]. However,
this limitation was also present in the evaluation of sleep from
actigraphy in control subjects and in multiple sessions of
actigraphic recordings, and may not, therefore, influence the
patients’ clinical monitoring. It should also be noted that in the
child affected by HAT the sleep time derived from actigraphy and
nocturnal PSG showed the same values, probably due to the fact
Figure 4. Characteristics of the rest-activity rhythm in patients
Y1 and Y2. A. Illustration of a RA tracing fitting curve (obtained with the
software provided by the manufacturer of the actigraphs: see Figure S1)
in a healthy subject (CY1). Note that it gives at a glance the graphic
demonstration of the daily waveform pattern. B. Illustration of the
characteristics of a rhythm. These parameters are automatically
computed using cosinor rhythmometry (see supplementary information
S2). C. Parameters of patient Y1 before treatment (T) and at 55 days after
treatment initiation, compared with control subject CY1. D. Parameters
of patient Y2 before treatment and 14 days after treatment initiation,
compared with control subject CY2. As explained in the text (see also
supplementaryinformationTextS1),theF-ratiovalue(valueofassociated
F-test)providesanestimateofthecharacteristicsoftherhythmshownby
the actigram waveform: the more the RA tracing is disrupted the lower is
the F-ratio value. Note in C and D the alterations of the waveform, and
the post-treatment improvement of its pattern (which, however, is still
altered), with corresponding increase of the F-ratio. Note also the
alterations of rhythm characteristics (with decrease of MESOR and
amplitude) which improve after treatment.
doi:10.1371/journal.pntd.0001525.g004
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CK7 (A–C) and patients K2–K7 at admission (D–I). The horizontal bars indicate the light and dark periods. WBC: white blood cell counts in the
cerebrospinal fluid.
doi:10.1371/journal.pntd.0001525.g005
Figure 6. Total sleep time in the adult patients K2–K7. The
analyses have been performed from actigraphic recordings (RA, rest-
activity) during the day (A) and night (C) and compared with matched
control subjects (CK2–CK7), and also from nocturnal polysomnography
(PSG) (C). B and D show the statistical evaluation for the day and night
values, respectively, and the horizontal bars indicate the mean value. As
in Fig. 2, ‘‘day’’ corresponds to the suggestive daily time of maximal
activity and ‘‘night’’ to the suggestive daily time interval of rest. The
numbers refer to white blood cell (WBC) counts in the cerebrospinal
fluid. In B and D: * P,0.05, Student’s unpaired t test.
doi:10.1371/journal.pntd.0001525.g006
Figure 7. Actigram of a child before treatment. The actigrams, 36-
h long, of a 5 year-old child affected by HAT (K1) and of a matched
control child CK1 (A) together with evaluations of the total sleep time
(B,C) are shown. The proportion of time spent asleep was evaluated
during the day from actigraphic recording (RA, rest-activity) (B), and
during the night from actigraphic and polysomnographic (PSG)
recordings (C). The horizontal bars in A indicate the light and dark
periods. WBC: white blood cell count in the cerebrospinal fluid.
doi:10.1371/journal.pntd.0001525.g007
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further supporting the use of this tool for the clinical evaluation of
children affected by HAT.
An interesting issue is raised by the correlation between the
signs of disease revealed by actigraphy and PSG on one hand, and
the WBC counts in the CSF on the other hand. In agreement with
previous investigation based on PSG [15,16] the patients with very
high number of WBCs in the CSF showed severe sleep-wake
changes (here revealed by both actigraphy and PSG), while in the
patients with lower numbers of WBCs (3–27 WBC/ml CSF in our
study) such correlation was not close. In addition, it has to be
noted that SOREM episodes were detected in our study also in
patients with 3–6 WBC/ml CSF, as shown in a previous study in
which SOREM episodes were detected in 2 out of 4 patients with
0–7 WBC/ml CSF, although the episodes were more frequent in
patients with .400 WBC/ml CSF [15].
Importantly, HAT brings about a severe neuroinflammatory
condition. Cytokines and chemokines are at the core of HAT
pathogenetic and clinical parameters, and inflammatory mediators
have been implicated in sleep disturbances during the disease
[18,41,42]. Novel experimental evidence has pointed out potential
laboratory biomarkers of HAT severity and stages [7,9–13]. The
correlation of actigraphic recordings and cytokine measurements
has already been validated in other conditions which lead to
increase of inflammatory biomarkers [43,44], also in children [45].
Such correlation could thus represent a precious diagnostic and
monitoring approach in HAT management.
On the basis of the results here presented, and despite the above
limitations, actigraphy appears as a tool well suited for objective
measurements of disturbed sleep pattern and the daily distribution
of sleep-wake in HAT patients, providing valuable neurophysio-
logical information. Considering the current interest to establish
scoring scales adapted to the clinical characteristics of the various
types of nervous system diseases, it is foreseen that such scoring
scales will be developed in the near future also for HAT to
improve the assessment of new treatments. Objective data
obtained by user-friendly actigraphy, standardized in a larger
cohort of HAT patients, could therefore be suited to be
incorporated into such novel scoring systems.
In conclusion, on the basis of this first published report,
actigraphy seems to be a very promising tool for obtaining objec-
tive clinical data in HAT, suited also for long-term assessment and
follow-up of HAT patients. This technique could therefore also be
useful for the clinical evaluation of relapses, assessment of novel
Figure 8. Characteristics of the rest-activity rhythm in DRC patients. The characteristics of the rest-activity (RA) rhythm in patients K1–K7 and
control subjects (A–F) are shown together with the assessment of statistical difference between adult control subjects and patients (H). A–F. All the
parameters have been evaluated as explained in the legend to Figure 4. Note the different degrees of alterations of the waveform (RA fitting curve),
of the F-ratio, acrophase (acr.), MESOR, and amplitude (ampl.). H: the statistical evaluation shows significant intergroup differences of the F-ratio,
acrophase, MESOR and amplitude; *P,0.05, **P,0.01, Student’s unpaired t test. Fcrit=3.68. For RA rhythms of all patients, F-ratio.Fcrit;P ,0.000001.
doi:10.1371/journal.pntd.0001525.g008
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body fluids which are currently under investigation in many
laboratories. This is of special relevance given that HAT affects
populations living in environments with precarious health facilities.
Supporting Information
Figure S1 Raw data of actigrams and steps followed in
data analysis.
(TIF)
Figure S2 Nocturnal hypnograms of patients K1–K7.
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